| Property | Value |
|---|
|
?:abstract
|
-
Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with COVID-19. Remdesivir is the prodrug of an adenosine analogue that inhibits viral replication of several RNA virus families including Coronaviridae Preclinical data in animal models of coronavirus diseases, including COVID-19, have demonstrated that early treatment with remdesivir leads to improved survival, decreased lung injury and decreased quantification of viral RNA. Recent clinical data have demonstrated the clinical activity of remdesivir in terms faster time to recovery in patients with severe COVID-19 and higher odds of improved clinical status in patients with moderate COVID-19. Clinical trials published to date are presented and appraised. Remdesivir\'s potential benefits and its favorable adverse event profile make it an option for the treatment of COVID-19. This article examines the available literature describing remdesivir\'s pharmacology, pharmacokinetics, and preclinical and clinical data.
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
|
|
?:journal
|
-
Antimicrobial_agents_and_chemotherapy
|
|
?:license
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}